The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human
NCT04298502 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2020-10-01
Summary
This is an observation study to investigate the molecular mechanism of NKG2C+NK cell expansion after HCMV infection
Conditions
- Acute Leukemia
- CMV Viremia
- Hematopoietic Stem Cell Transplantation
Sponsors & Collaborators
-
Peking University People's Hospital
lead OTHER
Principal Investigators
-
Xiaojun Huang, M.D., PhD · Peking University People's Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-01-01
- Primary Completion
- 2020-12-31
- Completion
- 2021-12-31
Countries
- China
Study Locations
More Related Trials
-
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
NCT05528341 ·Status: RECRUITING ·Phase: PHASE1
-
CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig
NCT03383055 ·Status: COMPLETED ·Phase: PHASE1
-
NK Cells Treatment for COVID-19
NCT04280224 ·Status: COMPLETED ·Phase: PHASE1
-
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
NCT05976906 ·Status: UNKNOWN ·Phase: PHASE1
-
PBMC Collection for Production of UCAR T Cells
NCT04963959 ·Status: UNKNOWN ·Phase: NA
-
MESA Treatment for NK/T Cell Lymphoma
NCT01933282 ·Status: UNKNOWN ·Phase: PHASE2
-
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
NCT00001582 ·Status: COMPLETED
-
NK Cell Infusion for Patients With Acute Myeloid Leukemia
NCT04221971 ·Status: UNKNOWN ·Phase: PHASE1
-
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
NCT00001158 ·Status: COMPLETED
-
Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid Tumors
NCT07274449 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer.
NCT02602249 ·Status: UNKNOWN ·Phase: PHASE1
-
Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
NCT04871165 ·Status: UNKNOWN
-
The Effects of Upper Airway and Digestive Tract Tumors on the Immune System
NCT00001603 ·Status: COMPLETED
-
Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation
NCT01795378 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
NCT00458536 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Thymic Function in Patients With COVID-19
NCT04716907 ·Status: COMPLETED
-
Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD
NCT06568328 ·Status: RECRUITING ·Phase: PHASE1
-
Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant
NCT01852591 ·Status: COMPLETED ·Phase: NA
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
NCT02479698 ·Status: RECRUITING ·Phase: PHASE2
-
Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies
NCT04878822 ·Status: UNKNOWN
-
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors
NCT06509490 ·Status: RECRUITING ·Phase: NA
-
In Vitro Studies of Immunological and Stem Cell Function in Peripheral Blood Mononuclear Cells in Patients
NCT00001336 ·Status: COMPLETED
-
Transcriptomics Signature of Anti Vaccinia Memory B Cells
NCT02556489 ·Status: UNKNOWN
-
Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy
NCT01884168 ·Status: COMPLETED
-
COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics
NCT04871932 ·Status: RECRUITING